Norwest Venture Partners
Norwest Venture Partners is a global technology venture capital firm founded in 1961 and based in California. It invests across venture and growth stages in the United States, India, Israel, and other markets, targeting software, cloud and IT infrastructure, information services, enterprise software and services, financial services, consumer products and healthcare. The firm backs entrepreneurs with capital plus an extensive network and operating experience to help scale their businesses. Since its inception it has backed hundreds of companies and manages a multi-billion-dollar portfolio, deploying capital in seed to growth rounds and across sectors that drive technology-enabled growth. Norwest emphasizes building lasting relationships with founders and mentoring teams through strategic guidance and market access to accelerate expansion and scale globally.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Indiana
MBX Biosciences
Series C in 2024
MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.
MBX Biosciences
Series B in 2022
MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.